Overview

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vaccinex Inc.
Collaborators:
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Alzheimer’s Drug Discovery Foundation